Archiv: Committee for Medicinal Products for Human Use (CHMP) / European Medicines Agency

25.06.2020 - 18:43 [ ]

Gilead’s remdesivir set to become Europe’s first COVID-19 therapy

The European Medicines Agency (EMA) said on Thursday its human medicines committee (CHMP) recommended conditionally approving the drug for adults and adolescents from 12 years of age who are also suffering from pneumonia and require oxygen support. (

European Union conditional marketing authorisation allows a treatment to be sold for a year in the 27-nation bloc before all necessary data on its efficacy and side-effects are available. Gilead has until December to submit this data.